Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal analysis of intrathecal baclofen therapy for hereditary spastic paraplegia
ChiCTR2500114250Phase 4Not yet recruiting
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of baclofen in hereditary spastic paraplegia (HSP), sponsored by The University of Hong Kong-Shenzhen Hospital. Primary endpoint: Spasm severity. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
baclofen
03
Conditions
hereditary spastic paraplegia (HSP)
Beyond the preview
Go deeper on ChiCTR2500114250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114250.